{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:50:18Z","timestamp":1794495018524,"version":"4.9.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFF1205000"],"award-info":[{"award-number":["2023YFF1205000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014764","name":"China International Medical Foundation","doi-asserted-by":"publisher","award":["Z-2018-35-2004"],"award-info":[{"award-number":["Z-2018-35-2004"]}],"id":[{"id":"10.13039\/501100014764","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Industry, University and Research Projects of the Ministry of Education","award":["2023HT035"],"award-info":[{"award-number":["2023HT035"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15094-9","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:01:28Z","timestamp":1763413288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Unraveling gut microbiome interferences in cancer immunotherapy: a meta-analysis of diverse drug effects"],"prefix":"10.1186","volume":"25","author":[{"given":"Jiaqiang","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingling","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"15094_CR1","doi-asserted-by":"publisher","first-page":"S1174","DOI":"10.1016\/j.annonc.2021.08.1643","volume":"32","author":"L Eng","year":"2021","unstructured":"Eng L, Sutradhar R, Niu Y, Liu N, Liu Y, Kaliwal Y, et al. 1671MO impact of antibiotic (ATB) exposure prior to immune checkpoint inhibitor (ICI) treatment on overall survival (OS): A population-based study. Ann Oncol. 2021;32:S1174\u20135.","journal-title":"Ann Oncol"},{"issue":"17","key":"15094_CR2","doi-asserted-by":"publisher","first-page":"17849","DOI":"10.1002\/cam4.6416","volume":"12","author":"K Nouso","year":"2023","unstructured":"Nouso K, Shiota S, Fujita R, Wakuta A, Kariyama K, Hiraoka A, et al. Effect of butyrate-producing Enterobacteria on advanced hepatocellular carcinoma treatment with Atezolizumab and bevacizumab. Cancer Med. 2023;12(17):17849\u201355.","journal-title":"Cancer Med"},{"issue":"19","key":"15094_CR3","doi-asserted-by":"publisher","first-page":"19530","DOI":"10.1002\/cam4.6565","volume":"12","author":"A Lasagna","year":"2023","unstructured":"Lasagna A, Mascaro F, Figini S, Basile S, Gambini G, Klersy C, et al. Impact of proton pump inhibitors on the onset of Gastrointestinal immune-related adverse events during immunotherapy. Cancer Med. 2023;12(19):19530\u20136.","journal-title":"Cancer Med"},{"key":"15094_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1155592","author":"M Chen","year":"2023","unstructured":"Chen M, Ma L, Yu H, Huang S, Zhang J, Gong J, et al. JK5G postbiotics attenuate immune-related adverse events in NSCLC patients by regulating gut microbiota: a randomized controlled trial in China. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1155592.","journal-title":"Front Oncol"},{"key":"15094_CR5","doi-asserted-by":"publisher","first-page":"109443","DOI":"10.1016\/j.bej.2024.109443","volume":"211","author":"A Mohammad","year":"2024","unstructured":"Mohammad A, Navid F, Saba F, Negar E, Prashant K, Amirhossein S. A comprehensive review on utilizing CRISPR\/Cas system for Microbiome modification. Biochem Eng J. 2024;211:109443.","journal-title":"Biochem Eng J"},{"key":"15094_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.716317","author":"Q Giordan","year":"2021","unstructured":"Giordan Q, Salleron J, Vallance C, Moriana C, Clement-Duchene C. Impact of antibiotics and proton pump inhibitors on efficacy and tolerance of anti-PD-1 immune checkpoint inhibitors. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.716317.","journal-title":"Front Immunol"},{"issue":"10","key":"15094_CR7","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.21873\/anticanres.15312","volume":"41","author":"K Hamada","year":"2021","unstructured":"Hamada K, Yoshimura K, Hirasawa Y, Hosonuma M, Murayama M, Narikawa Y, et al. Antibiotic usage reduced overall survival by over 70% in non-small cell lung cancer patients on anti-PD-1 immunotherapy. Anticancer Res. 2021;41(10):4985\u201393.","journal-title":"Anticancer Res"},{"issue":"4","key":"15094_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 Blockade with Cemiplimab in advanced cutaneous Squamous-Cell carcinoma. N Engl J Med. 2018;379(4):341\u201351.","journal-title":"N Engl J Med"},{"key":"15094_CR9","doi-asserted-by":"crossref","unstructured":"Ahmed J, Kumar A, Parikh K, Anwar A, Knoll BM, Puccio C et al. Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. Oncoimmunology. 2018;7(11):e1507670.","DOI":"10.1080\/2162402X.2018.1507670"},{"issue":"6","key":"15094_CR10","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","volume":"29","author":"L Derosa","year":"2018","unstructured":"Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29(6):1437\u201344.","journal-title":"Ann Oncol"},{"key":"15094_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100747","author":"DJ Pinato","year":"2023","unstructured":"Pinato DJ, Li X, Mishra-Kalyani P, D\u2019Alessio A, Fulgenzi CAM, Scheiner B, et al. Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma. JHEP Reports. 2023. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100747.","journal-title":"JHEP Reports"},{"issue":"9","key":"15094_CR12","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/ijc.34842","volume":"154","author":"A Morita","year":"2024","unstructured":"Morita A, Ichihara E, Inoue K, Fujiwara K, Yokoyama T, Harada D, et al. Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small\u2010cell lung cancer. Int J Cancer. 2024;154(9):1607\u201315.","journal-title":"Int J Cancer"},{"issue":"2","key":"15094_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/ijc.33557","volume":"149","author":"K Takada","year":"2021","unstructured":"Takada K, Shimokawa M, Takamori S, Shimamatsu S, Hirai F, Tagawa T, et al. Clinical impact of probiotics on the efficacy of anti-PD\u20101 monotherapy in patients with nonsmall cell lung cancer: a multicenter retrospective survival analysis study with inverse probability of treatment weighting. Int J Cancer. 2021;149(2):473\u201382.","journal-title":"Int J Cancer"},{"issue":"4","key":"15094_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","volume":"31","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020;31(4):525\u201331.","journal-title":"Ann Oncol"},{"issue":"7","key":"15094_CR15","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.urolonc.2022.02.020","volume":"40","author":"W Fukuokaya","year":"2022","unstructured":"Fukuokaya W, Kimura T, Komura K, Uchimoto T, Nishimura K, Yanagisawa T, et al. Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors. Urologic Oncology: Seminars Original Investigations. 2022;40(7):346.e1-.e8.","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"key":"15094_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092300","author":"K Homicsko","year":"2022","unstructured":"Homicsko K, Dummer R, Hoeller C, Wolchok JD, Hodi FS, Larkin J, et al. Proton pump inhibitor use and efficacy of nivolumab and ipilimumab in advanced melanoma. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14092300.","journal-title":"Cancers (Basel)"},{"key":"15094_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6267-z","author":"H Kim","year":"2019","unstructured":"Kim H, Lee JE, Hong SH, Lee MA, Kang JH, Kim I-H. The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study. BMC Cancer. 2019. https:\/\/doi.org\/10.1186\/s12885-019-6267-z.","journal-title":"BMC Cancer"},{"issue":"1","key":"15094_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00280-019-03993-1","volume":"85","author":"A Schett","year":"2019","unstructured":"Schett A, Rothschild SI, Curioni-Fontecedro A, Kr\u00e4henb\u00fchl S, Fr\u00fch M, Schmid S, et al. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors. Cancer Chemother Pharmacol. 2019;85(1):121\u201331.","journal-title":"Cancer Chemother Pharmacol"},{"key":"15094_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.lungcan.2019.01.017","volume":"130","author":"S Zhao","year":"2019","unstructured":"Zhao S, Gao G, Li W, Li X, Zhao C, Jiang T, et al. Antibiotics are associated with attenuated efficacy of anti-PD-1\/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. Lung Cancer. 2019;130:10\u20137.","journal-title":"Lung Cancer"},{"issue":"1","key":"15094_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1080\/1120009X.2020.1849488","volume":"33","author":"D Conde-Est\u00e9vez","year":"2020","unstructured":"Conde-Est\u00e9vez D, Monge-Escart\u00edn I, R\u00edos-Hoyo A, Monzonis X, Echeverr\u00eda-Esnal D, Moliner L, et al. Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockage. J Chemother. 2020;33(1):32\u20139.","journal-title":"J Chemother"},{"issue":"8","key":"15094_CR21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/hepr.13905","volume":"53","author":"T Hatanaka","year":"2023","unstructured":"Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, et al. Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving Atezolizumab and bevacizumab: a multicenter analysis. Hepatol Res. 2023;53(8):737\u201348.","journal-title":"Hepatol Res"},{"issue":"1","key":"15094_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41416-021-01606-4","volume":"126","author":"AM Hopkins","year":"2021","unstructured":"Hopkins AM, Kichenadasse G, McKinnon RA, Abuhelwa AY, Logan JM, Badaoui S, et al. Efficacy of first-line Atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. Br J Cancer. 2021;126(1):42\u20137.","journal-title":"Br J Cancer"},{"key":"15094_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.08.452","author":"M Husain","year":"2021","unstructured":"Husain M, Xu M, Patel S, Johns A, Grogan M, Li M, et al. P40.15 proton pump inhibitors, prior therapy and survival in patients treated with immune checkpoint inhibitors for advanced NSCLC. J Thorac Oncol. 2021. https:\/\/doi.org\/10.1016\/j.jtho.2021.08.452.","journal-title":"J Thorac Oncol"},{"key":"15094_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.22915","author":"H Kawachi","year":"2023","unstructured":"Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, et al. Concomitant proton pump inhibitor use with pembrolizumab monotherapy vs immune checkpoint inhibitor plus chemotherapy in patients with non\u2009\u2013\u2009small cell lung cancer. JAMA Netw Open. 2023. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.22915.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"15094_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11523-021-00861-y","volume":"17","author":"V Mollica","year":"2021","unstructured":"Mollica V, Santoni M, Matrana MR, Basso U, De Giorgi U, Rizzo A, et al. Concomitant proton pump inhibitors and outcome of patients treated with nivolumab alone or plus ipilimumab for advanced renal cell carcinoma. Target Oncol. 2021;17(1):61\u20138.","journal-title":"Target Oncol"},{"issue":"2","key":"15094_CR26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/bco2.118","volume":"3","author":"Y Okuyama","year":"2021","unstructured":"Okuyama Y, Hatakeyama S, Numakura K, Narita T, Tanaka T, Miura Y, et al. Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma. BJUI Compass. 2021;3(2):154\u201361.","journal-title":"BJUI Compass"},{"issue":"4","key":"15094_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/10600280211033938","volume":"56","author":"K Peng","year":"2021","unstructured":"Peng K, Chen K, Teply BA, Yee GC, Farazi PA, Lyden ER. Impact of proton pump inhibitor use on the effectiveness of immune checkpoint inhibitors in advanced cancer patients. Ann Pharmacother. 2021;56(4):377\u201386.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"15094_CR28","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.21873\/anticanres.15638","volume":"42","author":"I Tomisaki","year":"2022","unstructured":"Tomisaki I, Harada M, Minato A, Nagata Y, Kimuro R, Higashijima K, et al. Impact of the use of proton pump inhibitors on pembrolizumab effectiveness for advanced urothelial carcinoma. Anticancer Res. 2022;42(3):1629\u201334.","journal-title":"Anticancer Res"},{"key":"15094_CR29","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2081010","author":"Y Tomita","year":"2022","unstructured":"Tomita Y, Goto Y, Sakata S, Imamura K, Minemura A, Oka K, et al. Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors. Oncoimmunology. 2022. https:\/\/doi.org\/10.1080\/2162402X.2022.2081010.","journal-title":"Oncoimmunology"},{"key":"15094_CR30","first-page":"101189","volume":"16","author":"A Mohammad","year":"2024","unstructured":"Mohammad A, Negar E, Alireza K, Amirhossein S. Boosting vaccine effectiveness: the groundbreaking role of probiotics. J Agric Food Res. 2024;16:101189.","journal-title":"J Agric Food Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15094-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15094-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15094-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T09:02:36Z","timestamp":1763456556000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15094-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15094"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15094-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1776"}}